Awoke S, Voyles N R, Bhathena S J, Tanenberg R J, Recant L
Life Sci. 1984 May 21;34(21):1999-2006. doi: 10.1016/0024-3205(84)90364-3.
Plasma opioid levels were determined in 9 obese non-diabetic subjects, their 8 age matched controls, and in 29 diabetic patients; 10 maintained on diet alone, 6 on an oral hypoglycemic agent (chlorpropamide) and 13 treated with insulin. Five age matched controls for the diabetic groups were also studied for comparison. beta-endorphin and met-enkephalin levels were measured by radioimmunoassay. Enkephalin-like activity was measured by a receptor assay. Among the study groups, diabetic patients receiving insulin showed a 64% elevation of plasma beta-endorphins and diabetic patients on chlorpropamide showed a 121% increase in enkephalin-like activity. There were no statistically significant differences in the plasma met-enkephalin values in the treatment groups though levels were decreased (p less than 0.05) in diabetics vs non-diabetics. The pathophysiological importance of these alterations remains to be elucidated.
对9名肥胖非糖尿病受试者、8名年龄匹配的对照者以及29名糖尿病患者测定了血浆阿片样物质水平；其中10名仅通过饮食控制，6名服用口服降糖药（氯磺丙脲），13名接受胰岛素治疗。还研究了糖尿病组的5名年龄匹配的对照者以作比较。通过放射免疫分析法测定β-内啡肽和甲硫氨酸脑啡肽水平。通过受体分析法测定脑啡肽样活性。在研究组中，接受胰岛素治疗的糖尿病患者血浆β-内啡肽升高64%，服用氯磺丙脲的糖尿病患者脑啡肽样活性增加121%。各治疗组血浆甲硫氨酸脑啡肽值虽有下降（糖尿病患者与非糖尿病患者相比，p<0.05），但无统计学显著差异。这些改变的病理生理学重要性仍有待阐明。
